98%
921
2 minutes
20
A nano-theranostic system is reported that integrates imaging, detection, and treatment. The DNA assembly self-assembled by rolling circle amplification (RCA) product and four oligonucleotides are combined with MnO₂ nanosheets to construct DNA assembly@MnO₂. One repeat unit of the DNA assembly contains an aptamer module for specific targeting, a metal ion-activated intracellular imaging module, and a DNAzyme module for gene therapy (GT). Upon entering cancer cells, MnO₂ nanosheets are reduced to Mn⁺ by the high intracellular concentration of glutathione (GSH). On the one hand, Mn⁺ serves as a chemodynamic therapeutic agent to trigger Fenton-like reactions for chemodynamic therapy (CDT), and on the other hand, it can serve as a metal cofactor to activate the DNAzyme. This nanosystem can not only image specific cancer cells but also sensitively detect MCF-7 cells with a detection limit of 341 cells/mL. Moreover, this system can perform gene-chemodynamic combination therapy and has great application potential in cancer diagnosis and treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00604-025-07282-y | DOI Listing |
JAMA
September 2025
Division of Surgery and Interventional Science, UCL, London, United Kingdom.
Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.
View Article and Find Full Text PDFJAMA Cardiol
September 2025
Department of Cardiology, Inselspital University Hospital of Bern, University of Bern, Bern, Switzerland.
Importance: Right anomalous aortic origin of a coronary artery (R-AAOCA) is a rare congenital condition increasingly diagnosed with the growing use of cardiac imaging. Due to dynamic compression of the anomalous vessel, invasive fractional flow reserve (FFR) during a dobutamine-atropine volume challenge (FFR-dobutamine) is considered the reference standard. A reliable alternative method is needed to reduce extensive invasive testing, but it remains uncertain whether noninvasive imaging can accurately assess the hemodynamic relevance of R-AAOCA.
View Article and Find Full Text PDFJAMA Dermatol
September 2025
Department of Dermatology, University of Washington, Seattle.
Importance: Merkel cell carcinoma (MCC) is typically caused by the Merkel cell polyomavirus (MCPyV) and recurs in 40% of patients. Half of patients with MCC produce antibodies to MCPyV oncoproteins, the titers of which rise with disease recurrence and fall after successful treatment.
Objective: To assess the utility of MCPyV oncoprotein antibodies for early detection of first recurrence of MCC in a real-world clinical setting.
Aust Vet J
September 2025
Small Animal Specialist Hospital, North Ryde, New South Wales, Australia.
Syringomyelia is a common and heritable disorder in Cavalier King Charles Spaniels (CKCS), characterised by fluid accumulation within the spinal cord that may result in pain and neurological dysfunction. The prevalence of syringomyelia in CKCS in Australia has not previously been reported. The goal of this study was to assess the prevalence and severity of syringomyelia in magnetic resonance imaging (MRI)-screened breeding CKCS in New South Wales, Australia, from 2008 to 2024, and to evaluate changes over time.
View Article and Find Full Text PDFAnn Nucl Med
September 2025
Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey.
Objective: This study aims to systematically evaluate the inter- and intra-observer agreement regarding lesions with uncertain malignancy potential in Ga-68 PSMA PET/CT imaging of prostate cancer patients, utilizing the PSMA-RADS 2.0 classification system, and to emphasize the malignancy evidence associated with these lesions.
Methods: We retrospectively reviewed Ga-68 PSMA PET/CT images of patients diagnosed with prostate cancer via histopathology between December 2016 and November 2023.